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OBJECTIVES We compared a conventional stent (Jostent Flex, Jomed GmbH, Rangendingen, Germany)
with a polytetrafluoroethylene (PTFE)-membrane-covered stent (Jostent Stentgraft) in
patients undergoing intervention of a stenosis in an obstructed vein graft.
BACKGROUND The use of stents improved results of percutaneous revascularization of obstructed vein grafts,
but did not demonstrate the reduced elevated restenosis rate. In addition, long-term clinical
event rate is still high compared with intervention in native vessels. Observational studies
suggested that stents covered with a PTFE membrane might be associated with a low
complication and restenosis rate in venous bypass grafts.
METHODS This prospective multicenter study included a total of 211 patients who were randomly
assigned to receive either a Flex stent or Stentgraft. The primary end point was binary
restenosis rate at six months by core lab quantitative coronary angiography.
RESULTS Acute success and procedural events were comparable between the two groups. Restenosis
rate was not significantly different between the Flex (20%) and the Stentgraft (29%) groups
(p  0.15), although there was a nonsignificant trend toward a higher late occlusion rate in
the Stentgraft group (7% vs. 16%, p 0.069) at follow-up. Likewise, after a mean observation
period of 14 months, cumulative event rates (death, myocardial infarction, or target lesion
revascularization) were comparable in the two groups (31% vs. 31%, p  0.93).
CONCLUSIONS This controlled trial does not indicate a superiority of the PTFE-membrane-covered
Stentgraft compared with a conventional stent with respect to acute results, restenosis, or
clinical event rates. (J Am Coll Cardiol 2003;42:1360–9) © 2003 by the American College
of Cardiology Foundation
Saphenous vein graft coronary artery bypasses degenerate in
about one out of two patients within a decade after coronary
surgery (1). Because repeat surgery is associated with sub-
stantial risk, percutaneous interventional revascularization
seemed to be preferable. Furthermore, with the use of
intracoronary stents, major cardiac events, especially
procedure-related complications, could be substantially re-
duced compared with pure balloon angioplasty (2), but no
effect was obtained with respect to the high restenosis rate of
37% in bypass grafts. Likewise, long-term clinical outcome
is still poor despite the use of stents for interventional
treatment of obstructed bypass grafts (3,4). In addition,
elevation of creatine kinase (CK)-MB resulting from em-
bolization of atheromatous debris of the obstructed graft is
a strong independent predictor of late mortality—even in
otherwise uncomplicated interventions of venous bypass
grafts (5).
See page 1370
These findings provided the rationale to develop a stent
covered by a membrane in order to seal the lumen to reduce
microembolization and to reduce restenosis by preventing
protrusion of proliferating plaque material through the stent
mash. Initial experiences using the Jostent Coronary Stent-
graft (Jomed GmbH, Rangendingen, Germany), which has
a sandwich-like design with a biocompatible distensible
polytetrafluoroethylene (PTFE) membrane between two
stainless steel stents, were promising, when used in saphe-
nous vein grafts (6), and are a valuable bail-out anchor for
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treatment of percutaneous transluminal coronary angio-
plasty (PTCA)-related vessel rupture (6,7). Results of a
German multicenter registry suggested that the PTFE-
membrane-covered stent appears to be a safe and efficient
treatment strategy for obstructed vein grafts with restenosis
rates of about 17% (8). The present study, Stents IN Grafts
(STING), was designed as a prospective, randomized mul-
ticenter trial to compare the Jostent Coronary Stentgraft
with a conventional stent with respect to restenosis and
secondary cardiovascular events in patients undergoing per-
cutaneous intervention of obstructed coronary vein grafts.
METHODS
Patient population. Patients were eligible in the study
when they presented with angina pectoris or documented
myocardial ischemia and had by visual estimation a hemo-
dynamically significant de novo lesion in an aortocoronary
saphenous vein bypass graft with a lesion length between 5
and 45 mm and a reference diameter between 3.0 and 5.0
mm, accessible to percutaneous revascularization. The main
exclusion criteria were myocardial infarction (MI) 14 days
before intervention, Thrombolysis In Myocardial Infarction
(TIMI) flow 0 in the target vessel, restenotic lesion, distal
ostial lesion (5 mm), multiple lesions within the target
vessel, which cannot all be treated by the same stent type,
scheduled for surgery, severe hypertension, severe liver or
renal failure.
The study was performed in 12 centers in Germany and
Austria (see Appendix). The study protocol was approved
by the local ethics committee at each center. Written
informed consent was obtained before the procedure from
all patients.
Protocol. Patients were randomly assigned before the start
of the procedure to treatment with either Jostent Coronary
Stentgraft (hand-mounted) (Jomed GmbH, Rangendingen,
Germany) or Jostent Flex Coronary Stent by phone call to
a central office. Both stents have a Certificate of the
European Union and were available in the lengths 9, 16, and
26 mm. Patients were pretreated with aspirin (100 mg per
day). Heparin and abciximab (bolus and infusion over 12 h)
were recommended for all patients. Stent implantation
technique was performed at the discretion of the investiga-
tor. Ticlopidine (500 mg per day) or clopidogrel (75 mg per
day) were started after loading doses at the day of the
procedure and continued for three months. Control angiog-
raphy was scheduled after six months. A final interview to
assess clinical events was intended to be obtained after one
year (12  3 months). A clinical follow-up was available in
all patients intended to treat. However, in 15 patients (6
randomized to Flex and 9 to Stentgraft), a final interview
could only be obtained at the time of control angiography at
6 months.
Angiographic analysis. After intracoronary nitroglycerin,
coronary angiography was performed in two projections
before angioplasty, and identical projections were repeated
after the stent implantation procedure as well as at follow-
up. All angiograms were analyzed at the Frankfurt Univer-
sity Core Laboratory using a validated computer-assisted
quantitative angiography system (Medis-CMS, Leiden,
The Netherlands). Treatment allocation was not reported to
the analysts. Stenosis morphology and procedural events
were classified according to Ellis et al. (9) and Lincoff et al.
(10), and flow was determined according to the TIMI study
group (11). Procedural success was defined as a residual
stenosis after intervention 20% in the absence of peripro-
cedural events (death, MI).
End points. Primary end point was binary restenosis rate
(50% diameter stenosis) at six months follow-up. Late
occlusion was defined as a TIMI status1 at follow-up and
counted also as restenosis. If repeat angiography was pre-
maturely performed before 100 days for recurrence of
symptoms, it served as control angiography only if restenosis
was present. Secondary end point was a composite of clinical
events assessed after one year: occurrence of either death,
MI (CK elevation 3 upper normal limit with significant
MB fraction 6%), or target lesion revascularization
(PTCA at the site of the study stent or coronary artery
bypass grafting with new graft to target vessel). In addition,
target vessel revascularization (PTCA at any site of the
target bypass graft or coronary artery bypass grafting) and
non-target vessel revascularization were assessed.
Statistical analysis. We assumed a restenosis rate of 37%
in the conventional stent (Flex) group (2) and a restenosis
rate of 15% in the Stentgraft group (8). Using an  error of
0.05 and a power of 90%, a sample size of 210 patients is
required (164 patients with control angiography taking into
account a loss of follow-up). All analyses were reported
according to the intention-to-treat principle. Results were
reported as means ( SD) for continuous variables and as
percentage for categorical variables. For continuous vari-
ables, normal distribution was tested by Kolmogorov-
Smirnow test. Differences between the two groups were
tested by Student t test for normally distributed variables,
respectively by Mann-Whitney U test for non-normally
distributed variables. For categorical variables, chi-square
test or two-sided Fisher exact test (in case of 2  2
comparison with 5 expected observations in a cell) were
used. A p value of 0.05 was considered to be statistically
significant. All reported p values are two-sided. A stepwise
logistic regression analysis was performed to determine
independent predictors of late occlusions at six months. We
included in the model all clinical and angiographic variables
Abbreviations and Acronyms
CK  creatine kinase
MI  myocardial infarction
PTCA  percutaneous transluminal coronary
angioplasty
PTFE  polytetrafluoroethylene
STING  Stents IN Grafts trial
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that obtained a p value of 0.1 by univariate analysis.
Event-free survival curves were estimated according to the
Kaplan-Meier method and compared by the log-rank test.
For composite end points, the first event was counted.
RESULTS
Patient characteristics. Between April 1999 and January
2001, a total of 211 patients were randomized at 12 centers.
Five patients were excluded before intervention (Fig. 1), and
stent implantation was performed outside of the protocol.
Of those, one patient in the Flex group experienced peripro-
cedural resuscitation without MI and was discharged alive;
there were no clinical events in the other four patients at
long-term follow-up.
In the 206 patients included in the intention-to-treat
analysis, there were no differences between the Flex and the
Stentgraft group except the incidence of diabetes, which was
significantly more frequent in the Stentgraft group (Table 1).
Stent implantation procedure. There were no significant
differences with respect to lesion characteristics between the
two groups except calcification, which was significantly
more frequent in stenosis of patients in the Stentgraft group.
A significantly higher maximal balloon pressure was used in
patients in whom a stent graft was implanted compared
with the Flex group (Table 2), whereas balloon size,
number, and length of stents was similar between the
groups.
Of 102 patients assigned to the Stentgraft group, two
patients with distal occlusion after predilation or a very
proximal lesion did not receive any stent. In one patient
with a tortuous vessel, the assigned Stentgraft could not be
implanted, but conventional stents were successfully applied
(cross-over). No stent was lost during implantation. Com-
plete stent coverage of the stenosis was obtained in 99% in
the Flex and 96% in the Stentgraft group (p  0.21, Fisher
exact). Postprocedure minimal luminal diameter by quanti-
tative coronary angiography was comparable between the
two groups (Fig. 2A). Mean percent stenosis after the
intervention was 7.3  13% in the Flex and 6.6  14% in
the Stentgraft group (p  0.32, Mann-Whitney U).
Periprocedural events during the intervention were similar
between the groups (Table 3). There was one periprocedural
death in the Flex group (subsequent to periprocedural
infarction) and two deaths in the Stentgraft group (one
patient during the procedure due to a no-reflow phenome-
non with ST elevation and complete AV block after stent
Figure 1. Trial profile. *Index angiogram was not suitable for quantitative analysis in one patient. Angio  coronary angiogram; pt.  patient.
Table 1. Baseline Patient Characteristics
Characteristics
Flex
(n  104)
Stentgraft
(n  102) p Value
Age (yrs) 68  7.5 67  7.4 0.44†
Male gender 96 (92%) 88 (86%) 0.16‡
Unstable angina 21 (20%) 23 (23%) 0.68‡
Previous myocardial
infarction
46 (44%) 42 (41%) 0.66‡
Left ventricular ejection
fraction (%)*
54  16 55  14 0.91†
Age of vein graft (yrs) 10.6  4.8 9.5  5.1 0.12†
Hypercholesterolemia 77 (74%) 72 (71%) 0.58‡
Hypertension 73 (70%) 73 (72%) 0.83‡
Diabetes mellitus 20 (19%) 33 (32%) 0.031‡
Smoker 55 (53%) 42 (41%) 0.092‡
Beta-blocker 74 (71%) 75 (74%) 0.70‡
ACE inhibitor 56 (54%) 59 (58%) 0.56‡
*Visual estimation, determined in 66 Flex and 55 Stentgraft patients; †t test;
‡chi-square test.
ACE  angiotensin-converting enzyme.
1362 Scha¨chinger et al. JACC Vol. 42, No. 8, 2003
Covered Stents in Saphenous Vein Graft PTCA October 15, 2003:1360–9
implantation and one patient on day 2 due to pulmonary
bleeding related to glycoprotein IIb/IIIa receptor blockade).
Angiographic outcome. In 82% of the 206 patients (n 
168), where a timely follow-up angiography (181  39 days
after stent implantation) was available, baseline and postint-
ervention quantitative measurements were comparable be-
tween the Flex and Stentgraft groups (Table 4). At follow-
up, there were no statistically significant differences in
minimal luminal diameter or percent stenosis between the
groups. With respect to the primary end point restenosis
rate at six months, there was also no significant difference
between the Flex (20%) and Stentgraft groups (29%) (p 
0.15). Angiographic pattern of restenosis differed between
the groups; excluding late occlusions, minimal luminal
diameter was more frequently within the medial part of the
stent body (vs. the edges) in the Flex group (7 of 11)
compared with the Stentgraft group (1 of 11; p  0.024,
Fisher exact test).
In patients with angiographically documented absence of
restenosis at 6 months, subsequent target vessel revascular-
ization during the clinical follow-up period (median, 14
months) was infrequently necessary in 3 patients (1 Stent-
graft, 2 Flex) by percutaneous intervention and 2 patients
(Stentgraft) by bypass surgery.
There was a tendency toward a higher occlusion status at
follow-up in the Stentgraft group versus the Flex group (n
 13 vs. 6) (Table 4). However, this difference did not reach
statistical significance by univariate as well as multivariate
analysis (Table 5). One patient in the Stentgraft group
suffered subacute stent thrombosis and MI two days after
the procedure (Stentgraft) without subsequent intervention,
and one patient in the Flex group experienced subacute stent
thrombosis undergoing successful reintervention without
MI. However, both patients demonstrated late occlusion at
six months angiography. Two additional patients experi-
enced CK elevation in association with occlusion of the
study vessel of 117 U/l 121 days (Flex), respectively 250 U/l
125 days (Stentgraft), after stent implantation, and re-
PTCA was performed. Interestingly, in none of the other 16
patients with late occlusion seen by angiography 150 days
after stent implantation was an MI documented. In these
patients, target vessel revascularization was performed in four
(Stentgraft), respectively five (Flex), patients. One patient with
documented late occlusion subsequently died during clinical
follow-up from cardiovascular cause (Flex) and one patient
died from noncardiovascular cause (Stentgraft).
In five patients (three Stentgraft, two Flex), only a
premature angiogram was obtained demonstrating no reste-
Table 2. Lesion and Procedural Characteristics
Flex
(n  104)
Stentgraft
(n  102) p Value
Lesion
Target bypass distribution 0.46†
LAD 38 (37%) 40 (39%)
RCX 44 (42%) 35 (34%)
RCA 22 (21%) 27 (27%)
Sequential bypass 9 (8.7%) 8 (7.8%) 0.83‡
Multiple dilations
Same vessel 8 (7.7%) 14 (14%) 0.16‡
Other vessel 7 (6.7%) 2 (2.0%) 0.17§
Stenosis morphology
Calcification 4 (3.8%) 12 (12%) 0.034‡
Complex morphology 29 (28%) 29 (28%) 0.93‡
Bending 45° 13 (13%) 17 (17%) 0.40‡
TIMI status before intervention 0.98‡
0 1 (1%) 1 (1%)
1 3 (2.9%) 4 (3.9%)
2 17 (16%) 17 (17%)
3 83 (80%) 80 (78%)
Procedure
Balloon size (mm) 3.9  0.50 3.8  0.52 0.37†
Maximal balloon pressure (atm) 15.0  2.7 16.4  2.6  0.001†
Balloon/reference ratio 1.15  0.17 1.16  0.20 0.62*
Stent lengths ( in mm) 19.0  8.3 18.4  8.4 0.53†
Number of stents implanted 0.38‡
0 0 2 (2%)
1 83 (80%) 85 (83%)
2 20 (19%) 14 (14%)
3 1 (1%) 1 (1%)
Crossover 0 1 (1%) 0.50§
Protection device used 10 (9.6%) 9 (8.8%) 0.84‡
*t test; †Mann-Whitney U test; ‡chi-square test; §Fisher exact test.
LAD  left anterior descending coronary artery; RCA  right coronary artery; RCX  right circumflex artery; TIMI 
Thrombolysis In Myocardial Infarction.
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nosis. There were no deaths, MIs, or target vessel revascu-
larizations at follow-up in these patients.
Clinical outcome. There were no statistically significant
differences in individual or combined clinical events at 30
days or 6 months (Table 6).
Long-term clinical follow-up was obtained after a mean
of 14  2.1 months in the Flex group and 14  2.8 months
in the Stentgraft group. There was no difference in the
secondary end point of cumulative event rate (death, MI, or
target lesion revascularization) between the Flex and Stent-
graft group by chi-square test (Table 6) or Kaplan-Meier
analysis (Fig. 3A). In addition, there was no significant
difference with respect to the components of the end points
between the two groups (Table 6, Figs. 3B and 3C). The
cause of death in the Flex versus Stentgraft group was
cardiovascular death in four versus five patients with sudden
death occurring in three out of four patients versus one
patient out of five, respectively; noncardiovascular death in
one versus two patients and unknown cause of death in one
versus two patients, respectively. Because some patients
with late occlusion did not undergo revascularization, a
combined end point of death, MI, or angiographically
documented restenosis was calculated. There was a ten-
dency, albeit statistically not significant, toward a higher
Figure 2. Cumulative distribution of minimal luminal diameter (MLD) assessed by quantitative coronary angiography. (A) Patients intended to treat: MLD
before intervention and after intervention. (B) Patients undergoing follow-up angiography: MLD after intervention and at follow-up. Diamond 
Stentgraft; circle  Flex; dotted  after intervention.
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event rate in the Stentgraft group (26% vs. 37%, p  0.081,
chi-square test).
DISCUSSION
Despite the fact that stents have improved the outcome of
percutaneous intervention of obstructed vein grafts (2,3),
prognosis of patients undergoing this procedure is still poor
(4,12). Targets to improve intervention in saphenous vein
grafts are to inhibit distal embolization of atherosclerotic
debris (13) and to reduce restenosis rate, which is elevated
compared with native vessels (2,4,14). Thus, it was intrigu-
ing to hypothesize that a stent covered with a membrane
would seal the lumen and prevent protrusion of proliferating
tissue and, thereby, reduce microembolization and resteno-
sis rate. However, the present trial does not reveal a benefit
of the PTFE-membrane-covered Jostent Stentgraft com-
pared with the conventional stent used (Jostent Flex);
restenosis rate, the primary end point, did not significantly
differ between the Stentgraft (29%) and the conventional
Table 6. Occurrence of Clinical Events During Follow-Up
Characteristics
Flex
(n  104)
Stentgraft
(n  102)
p
Value
30 days
Death 1 (1%) 3 (2.9%) 0.37†
Myocardial infarction 6 (5.8%) 5 (4.9%) 0.78†
TLR 1 (1%) 0 0.99†
Cumulative death, MI, or TLR 7 (6.7%) 8 (7.8%) 0.76*
6 months
Death 3 (2.9%) 7 (6.9%) 0.21†
MI 8 (7.7%) 8 (7.7%) 0.97*
TLR 13 (13%) 7 (6.9%) 0.17*
Cumulative death, MI, or TLR 22 (21%) 20 (20%) 0.78*
Up to 15 months
Death 6 (5.8%) 9 (8.8%) 0.40*
MI 8 (7.7%) 10 (9.8%) 0.59*
Site of revascularization
TLR 22 (21%) 17 (17%) 0.41*
TVR 25 (24%) 20 (20%) 0.44*
Nontarget vessel 10 (9.6%) 12 (12%) 0.62*
Revascularization (TVR or
nontarget vessel)
34 (33%) 29 (28%) 0.51*
PTCA 33 (32%) 25 (25%) 0.25*
CABG 1 (1%) 5 (5%) 0.12†
Secondary end point: 32 (31%) 32 (31%) 0.93*
Cumulative death, MI, or TLR
*Chi-square test; †Fisher exact test.
CABG  coronary artery bypass grafting; MI  myocardial infarction; PTCA 
percutaneous transluminal coronary angioplasty; TLR  target lesion revasculariza-
tion; TVR  target vessel revascularization.
Table 3. Periprocedural Events
Flex
(n  104)
Stentgraft
(n  102) p Value
Procedural dissection 16 (15%) 15 (15%) 0.89‡
Abrupt closure 7 (6.7%) 3 (2.9%) 0.33§
Distal embolization 5 (4.8%) 5 (4.9%) 0.98§
TIMI status postintervention 0.78‡
0 1 (1%) 1 (1%)
1 1 (1%) 0
2 6 (6%) 5 (5%)
3 96 (93%) 96 (94%)
Periprocedural death 1 (1%) 2 (2%) 0.62§
Periprocedural myocardial
infarction
6 (5.6%) 5 (4.9%) 0.78‡
CKmax (U/I) 486  210 398  107 0.40*
Procedural success 93 (89%) 89 (87%) 0.63‡
Days postprocedure intensive
care unit
0.35  0.67 0.36  0.73 0.93†
*t test; †Mann-Whitney U test; ‡chi-square test; §Fisher exact test.
CK  creatine kinase; TIMI  Thrombolysis In Myocardial Infarction.
Table 4. Quantitative Coronary Angiography of Patients With
Angiographic Follow-Up
Characteristics
Flex
(n  86)
Stentgraft
(n  82)
p
Value
Minimal lumen diameter
(mm)
Before 1.27  0.59 1.26  0.54 0.79†
After 3.25  0.44 3.29  0.45 0.53*
Follow-up 2.29  0.96 2.10  1.17 0.24†
Reference diameter
(mm)
Before 3.42  0.59 3.32  0.61 0.16†
After 3.50  0.52 3.48  0.59 0.71†
Follow-up 3.46  0.50 3.31  0.62 0.05†
Percent stenosis
Before 64  15 63  14 0.48†
After 6.6  9.0 4.5  9.8 0.17*
Follow-up 33  26 36  34 0.81†
Acute gain (mm) 2.0  0.57 2.0  0.63 0.61†
Late loss (mm) 0.95  0.97 1.17  1.07 0.29†
Net gain (mm) 1.03  0.96 0.87  1.05 0.26†
Restenosis rate (50%
diameter stenosis)
17 (20%) 24 (29%) 0.15‡
Occlusion at follow-up 6 (7.0%) 13 (16%) 0.069‡
*t test; †Mann-Whitney U test; ‡chi-square test.
Table 5. Variables Associated With Late Occlusion at
Follow-Up Angiography
Univariate
Analysis
p Value
Multivariate Regression
Analysis
Standardized
Coefficient p Value
Stent graft 0.069§ 0.12 0.095
Diabetes mellitus 0.007 0.18 0.011
Unstable angina 0.22 –
Low TIMI status before
intervention
 0.001§ 0.29  0.001
Intermittent vessel
occlusion
0.032 0.16 0.021
Residual dissection 0.032 0.12 0.10
Stent length 0.56‡ –
Percent stenosis after
intervention
0.47† –
Left ventricular ejection
fraction*
0.30† –
R 0.46
Model summary Adjusted R2 0.19
Significance
(ANOVA)
p  0.001
*Available in 99 patients; †t test; ‡Mann-Whitney U test; §chi square test; Fisher
exact test.
ANOVA analysis of variance; TIMI Thrombolysis In Myocardial Infarction.
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stent group (20%). In addition, acute complications and
long-term clinical event rate up to 15 months were compa-
rable between the two groups.
Important to note is that the restenosis rate in both
groups was lower in the present study than recently reported
from vein graft stenting ranging from 34% to 43% (2,4,14).
Patients in the conventional stent group had a most favor-
able angiographic outcome, making it unlikely to demon-
strate a superiority of the Stentgraft. These favorable results
might be related to patient selection, because the present
study did not intend to treat stenosis at an ostial or distal
anastomosis location as well as total occlusion, all known to
be associated with a less favorable outcome (13,15), and
reference vessel diameter was approximately 0.2 mm larger
than in recent studies (2,14). In addition, acute angio-
graphic success was advantageous in both groups of the
present trial compared with the previous studies (2,14), with
minimal luminal diameter after intervention being more
than 0.4 mm larger and a residual percent stenosis being
less, with 6.6% compared with 12% in previous studies
(2,14).
The comparable results between the Stentgraft and the
conventional stent were obtained despite the fact that
baseline characteristics were unfavorable for the Stentgraft
Figure 3. Kaplan-Meier analyses of cumulative event rates. (A) Cumulative event rate of secondary end point: death, myocardial infarction (MI), or target
lesion revascularization (TLR). (B) Cumulative event rate: death or MI. Continued on next page.
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group with a significantly higher rate of lesion calcification
and patients with diabetes mellitus (33% vs. 19%). The
latter is known to be a powerful predictor, not only for
restenosis, but also for adverse acute and long-term clinical
events in patients undergoing percutaneous intervention of
obstructed vein grafts (14,16). Nevertheless, the outcome of
the Stentgraft group was worse than the expectations
resulting from a previous surveillance trial of 109 patients
with 17% restenosis and 11% target lesion revascularization
compared with 29% restenosis and 24% target vessel revas-
cularization in the present study. Despite similar minimal
lumen diameter after stent implantation, late loss was 0.4
mm higher in the present study compared with the registry.
This phenomenon of discrepancy between the results of a
registry and the subsequent randomized trial has also been
made in previous studies assessing stent implantation in
native vessels (18% vs. 28% restenosis in Stent Restenosis
Study [STRESS]) (17,18) or saphenous vein grafts (22% vs.
37% restenosis in Saphenous Vein De Novo Trial
[SAVED]) (2,19).
The rate of major adverse clinical events, which predom-
inantly occurred during the first nine months, did not
significantly differ between patients randomized to Stent-
graft versus the conventional stent and were comparable to
the stent group in the randomized SAVED trial reporting
7% death, 11% MI, and 17% target lesion revascularization
up to 240 days after the procedure (2). However, a notice-
able finding is that the rate of late occlusion was doubled in
the Stentgraft group compared with the conventional stent
group (13% vs. 6%), even though this difference did not
reach statistical significance by univariate as well as multi-
variate analysis in the tested sample size. Late occlusion is a
known problem associated with stenting of obstructed vein
grafts reported to occur in 4% (14) to more than 10% (2) of
the cases receiving a conventional stent and 9% in the recent
registry of the Jostent Stentgraft (8). In most patients in the
present study, late occlusion was documented beyond the
three-month period, in which case therapy with ticlopidine
or clopidogrel was intended by the protocol. Thus, one
might speculate whether a postponed re-endothelialization
or enhanced thrombogenicity of the PTFE membrane
might predispose for late thrombotic occlusions. However,
the clinical course of most documented late occlusions was
surprisingly benign, with only few cases associated with an
MI. Obviously, the present study cannot disclose whether a
prolonged therapy with thienopyridines would have had an
impact on late occlusions. However, the fact that late
occlusions 150 days were not associated with MI might
indicate that progressively proliferating restenosis, rather
than acute thrombosis, might be the mechanism of late
occlusion in these patients.
Study limitations. Although the study was prospective and
randomized, patients as well as investigators were not
blinded with respect to the treatment group, which might
have influenced the results. Indeed, reluctance to revascu-
larize a restenotic lesion after 6 months was 1 (occluded)
restenosis out of 17 in the Flex group versus 11 out of 24 in
the Stentgraft group. In the latter group, especially occluded
vessels were not repeatedly revascularized (8 of 13 not
treated), which might have obscured target lesion revascu-
larization rate in favor of the Stentgraft group. However, the
findings of the study are additionally based on the objective
analysis of quantitative angiographic parameters using a
standardized automatic edge detection system by a central
core lab as well as hard end points such as death or MI,
which are in line with the overall finding of the study.
The study was not powered to detect a difference in death
or MI rates itself. In addition, a larger population might be
needed to definitely disclose a potential impact of a PTFE-
membrane-covered stent on the incidence of restenosis and
Figure 3 Continued. (C) Cumulative event rate: TLR.
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late occlusions. The results of two further studies ongoing in
Italy (Randomized Evaluation of Polytetrafluoroethylene
Covered Stent in Saphenous Vein Grafts [RECOVERS])
and the U.S. (BARRICADE) will probably add the desired
information in conjunction with the present study.
The equivalence between the conventional stent and the
Stentgraft cannot be transferred to other PTFE-membrane-
covered stents. By design—having a PTFE-membrane
fixed between two stainless steel stents—the Stentgraft in
the present study is somewhat bulky, which is reflected by
the fact that a higher balloon pressure was used compared
with the conventional stent group in order to completely
expand the stent. Future refinements of the Stentgraft
design might be associated with a more favorable clinical
outcome.
After completion of the inclusion into this trial, the
results of the Saphenous Vein Graft Angioplasty Free of
Emboli Randomized Trial (SAFER) (20) were published,
demonstrating a reduction of major cardiovascular events by
42% with a protection device, which was used in less than
10% of the cases in the present study. However, there was
no evidence that the Stentgraft substantially reduces the risk
of atheromatous microembolism because the angiographi-
cally visible embolism, abrupt vessel closure, TIMI status
after intervention, and the rate of postprocedural MIs were
comparable between the two groups. Thus, it cannot be
expected that the routine use of protection devices will
uncover a difference between the two tested stent types. In
addition, even though the effect of the glycoprotein IIb/IIIa
inhibitor on microembolism in vein graft stenting is under
debate (21,22), routine use of abciximab was mandatory in
the present study.
Meanwhile, intracoronary brachytherapy has been proven
to reduce restenosis rates and cardiovascular events by
approximately 50% when treating an in-stent restenosis in
an obstructed vein graft (23). It is not known whether this
beneficial therapy might be used with the same success for
treatment of restenosis of a PTFE-membrane-covered
stent.
Furthermore, the double layer of PTFE may be disad-
vantageous for neointimal growth. Recent designs use a
porous single membrane or provide a collagen-like matrix
for endothelial cell growth (24). In addition, antiprolifera-
tive agents may be added to achieve better results in the
future (25).
Conclusions. The present STING study does not indicate
a superiority of stent grafts compared with conventional
stents with respect to restenosis or clinical events, as it has
been suspected by the previous retrospective data. Two
additional findings were striking; first, restenosis rate in the
conventional stent group was lower than expected from
previous studies, making it unlikely to demonstrate a dif-
ference between the two stents. Second, there was a ten-
dency—albeit statistically not significant—toward a higher
rate of total occlusions at follow-up in the stent graft group
compared with the conventional stent. However, before a
final assessment of the role of membrane-covered stent
grafts in the treatment of aortocoronary venous grafts can be
made, final analysis of all ongoing studies should be awaited.
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APPENDIX
In addition to the authors, the following institutions and
investigators participated in the STING trial:
Steering Committee: Ch. Hamm (chairman), A. M.
Zeiher, J. Berger (statistics).
Safety Monitoring Board: B. Meier, H. J. Rupprecht.
Coronary Angiography Core Lab: A. M. Zeiher, V.
Scha¨chinger.
Participating Centers (the number of patients enrolled at each
center appears in parenthesis): Germany: Universita¨tsklini-
kum Eppendorf, Hamburg: T. Mu¨nzel, S. Baldus, R.
Ko¨ster, F. Cortes (45); Universita¨tsklinikum, Essen: R.
Erbel, M. Haude, T. Konorza (30); Kerckhoff Klinik, Bad
Nauheim: Ch. Hamm, R. Arnold (28); Krankenhaus, Sieg-
burg: E. Grube, R. Mu¨ller (24); Sta¨dtisches Klinikum,
Fulda: T. Bonzel, R. Biesner, R. Ibing (19); J. W. Goethe
Universita¨t, Frankfurt/Main: A. M. Zeiher, V. Scha¨ch-
inger, W. Auch-Schwelk (15); Rotes-Kreuz Krankenhaus,
Frankfurt/Main: J. Haase, F. Braun (14); Klinikum der
Rhein.-Westf. TH: J. vom Dahl, P. Haager (9); Dt.
Herzzentrum, Mu¨nchen: F. J. Neumann, F. Pogatsa-
Murray (7); Krankenhaus, Mu¨nchen-Neuperlach: H.
Mudra, A. Knape (7); Universita¨tskliniken des Saarlandes,
Homburg/Saar: M. Bo¨hm, B. Hennen (3). Austria: Allge-
meines Krankenhaus Wien: P. Probst, I. Lang (10).
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